Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus NALLPEN.
AMPICILLIN TRIHYDRATE vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic